The UT Horizon Fund has participated in a $14.3m series B round for Lung Therapeutics.

Lung Therapeutics, a life sciences spinout of  University of Texas Health Science Center at Tyler, has raised $14.3m in a series B round featuring UT Horizon Fund, a strategic investment fund of University of Texas System.

Private equity firm Bios Partners led the series B round for Lung Therapeutics.

Lung Therapeutics is working on treatments for life-threatening lung conditions.

The latest round will be used to support ongoing clinical trials of its lead program LTI-01 in Australia and New Zealand.